vs
NEOGEN CORP（NEOG）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
QuidelOrtho Corp的季度营收约是NEOGEN CORP的3.1倍（$699.9M vs $224.7M）。NEOGEN CORP净利率更高（-7.1% vs -104.7%，领先97.6%）。NEOGEN CORP同比增速更快（-2.8% vs -3.7%）。NEOGEN CORP自由现金流更多（$7.8M vs $-94.7M）。过去两年NEOGEN CORP的营收复合增速更高（-0.9% vs -2.9%）
Neogen Corporation是一家1982年成立、总部位于美国密歇根州兰辛的跨国食品安全企业，专注提供各类检测试剂盒及相关产品，用于筛查食品中的有害成分。目前业务覆盖美国、加拿大、英国、欧洲部分地区、墨西哥、巴西、印度、中国等多个国家，旗下拥有超100款药物检测试剂盒产品，可检测约300种相关违禁物质。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
NEOG vs QDEL — 直观对比
营收规模更大
QDEL
是对方的3.1倍
$224.7M
营收增速更快
NEOG
高出0.9%
-3.7%
净利率更高
NEOG
高出97.6%
-104.7%
自由现金流更多
NEOG
多$102.5M
$-94.7M
两年增速更快
NEOG
近两年复合增速
-2.9%
损益表 — Q2 2026 vs Q3 2026
| 指标 | | |
|---|---|---|
| 营收 | $224.7M | $699.9M |
| 净利润 | $-15.9M | $-733.0M |
| 毛利率 | 47.5% | — |
| 营业利润率 | -2.4% | -100.7% |
| 净利率 | -7.1% | -104.7% |
| 营收同比 | -2.8% | -3.7% |
| 净利润同比 | 96.5% | -3583.4% |
| 每股收益（稀释后） | $-0.07 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收NEOGQDEL
| Q4 25 | $224.7M | — | ||
| Q3 25 | $209.2M | $699.9M | ||
| Q2 25 | $225.4M | $613.9M | ||
| Q1 25 | $221.0M | $692.8M | ||
| Q4 24 | $231.3M | $707.8M | ||
| Q3 24 | $217.0M | $727.1M | ||
| Q2 24 | $236.8M | $637.0M | ||
| Q1 24 | $228.8M | $711.0M |
净利润NEOGQDEL
| Q4 25 | $-15.9M | — | ||
| Q3 25 | $36.3M | $-733.0M | ||
| Q2 25 | $-612.3M | $-255.4M | ||
| Q1 25 | $-10.9M | $-12.7M | ||
| Q4 24 | $-456.3M | $-178.4M | ||
| Q3 24 | $-12.6M | $-19.9M | ||
| Q2 24 | $-5.4M | $-147.7M | ||
| Q1 24 | $-2.0M | $-1.7B |
毛利率NEOGQDEL
| Q4 25 | 47.5% | — | ||
| Q3 25 | 45.4% | — | ||
| Q2 25 | 41.2% | — | ||
| Q1 25 | 49.9% | — | ||
| Q4 24 | 49.0% | — | ||
| Q3 24 | 48.4% | — | ||
| Q2 24 | 47.9% | — | ||
| Q1 24 | 51.1% | — |
营业利润率NEOGQDEL
| Q4 25 | -2.4% | — | ||
| Q3 25 | -7.7% | -100.7% | ||
| Q2 25 | -271.1% | -29.4% | ||
| Q1 25 | 2.4% | 4.7% | ||
| Q4 24 | -197.8% | -14.2% | ||
| Q3 24 | 1.0% | 2.1% | ||
| Q2 24 | 5.5% | -18.4% | ||
| Q1 24 | 5.3% | -247.3% |
净利率NEOGQDEL
| Q4 25 | -7.1% | — | ||
| Q3 25 | 17.4% | -104.7% | ||
| Q2 25 | -271.6% | -41.6% | ||
| Q1 25 | -4.9% | -1.8% | ||
| Q4 24 | -197.3% | -25.2% | ||
| Q3 24 | -5.8% | -2.7% | ||
| Q2 24 | -2.3% | -23.2% | ||
| Q1 24 | -0.9% | -239.9% |
每股收益（稀释后）NEOGQDEL
| Q4 25 | $-0.07 | — | ||
| Q3 25 | $0.17 | $-10.78 | ||
| Q2 25 | $-2.82 | $-3.77 | ||
| Q1 25 | $-0.05 | $-0.19 | ||
| Q4 24 | $-2.10 | $-2.54 | ||
| Q3 24 | $-0.06 | $-0.30 | ||
| Q2 24 | $-0.02 | $-2.20 | ||
| Q1 24 | $-0.01 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $145.3M | $98.1M |
| 总债务越低越好 | — | $2.5B |
| 股东权益账面价值 | $2.1B | $2.0B |
| 总资产 | $3.4B | $5.7B |
| 负债/权益比越低杠杆越低 | — | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资NEOGQDEL
| Q4 25 | $145.3M | — | ||
| Q3 25 | $138.9M | $98.1M | ||
| Q2 25 | $129.0M | $151.7M | ||
| Q1 25 | $127.7M | $127.1M | ||
| Q4 24 | $140.2M | $98.3M | ||
| Q3 24 | $120.5M | $143.7M | ||
| Q2 24 | $170.9M | $107.0M | ||
| Q1 24 | $168.4M | $78.5M |
总债务NEOGQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | $2.5B | ||
| Q2 25 | — | $2.1B | ||
| Q1 25 | — | $2.1B | ||
| Q4 24 | — | $2.1B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | — | $2.2B | ||
| Q1 24 | — | $2.2B |
股东权益NEOGQDEL
| Q4 25 | $2.1B | — | ||
| Q3 25 | $2.1B | $2.0B | ||
| Q2 25 | $2.1B | $2.8B | ||
| Q1 25 | $2.7B | $3.0B | ||
| Q4 24 | $2.7B | $3.0B | ||
| Q3 24 | $3.1B | $3.2B | ||
| Q2 24 | $3.1B | $3.2B | ||
| Q1 24 | $3.1B | $3.3B |
总资产NEOGQDEL
| Q4 25 | $3.4B | — | ||
| Q3 25 | $3.4B | $5.7B | ||
| Q2 25 | $3.4B | $6.4B | ||
| Q1 25 | $4.0B | $6.5B | ||
| Q4 24 | $4.1B | $6.4B | ||
| Q3 24 | $4.5B | $6.8B | ||
| Q2 24 | $4.5B | $6.7B | ||
| Q1 24 | $4.6B | $6.7B |
负债/权益比NEOGQDEL
| Q4 25 | — | — | ||
| Q3 25 | — | 1.23× | ||
| Q2 25 | — | 0.74× | ||
| Q1 25 | — | 0.70× | ||
| Q4 24 | — | 0.72× | ||
| Q3 24 | — | 0.68× | ||
| Q2 24 | — | 0.70× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $19.4M | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | $7.8M | $-94.7M |
| 自由现金流率自由现金流/营收 | 3.5% | -13.5% |
| 资本支出强度资本支出/营收 | 5.2% | 7.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-18.5M | $-153.1M |
8季度趋势，按日历期对齐
经营现金流NEOGQDEL
| Q4 25 | $19.4M | — | ||
| Q3 25 | $10.9M | $-45.5M | ||
| Q2 25 | $16.4M | $-46.8M | ||
| Q1 25 | $19.5M | $65.6M | ||
| Q4 24 | $40.3M | $63.7M | ||
| Q3 24 | $-17.9M | $117.9M | ||
| Q2 24 | $26.7M | $-97.9M | ||
| Q1 24 | $-30.2M | $-700.0K |
自由现金流NEOGQDEL
| Q4 25 | $7.8M | — | ||
| Q3 25 | $-13.1M | $-94.7M | ||
| Q2 25 | $349.0K | $-84.3M | ||
| Q1 25 | $-13.4M | $9.4M | ||
| Q4 24 | $23.1M | $16.5M | ||
| Q3 24 | $-56.3M | $71.4M | ||
| Q2 24 | $2.5M | $-133.2M | ||
| Q1 24 | $-62.3M | $-66.8M |
自由现金流率NEOGQDEL
| Q4 25 | 3.5% | — | ||
| Q3 25 | -6.3% | -13.5% | ||
| Q2 25 | 0.2% | -13.7% | ||
| Q1 25 | -6.1% | 1.4% | ||
| Q4 24 | 10.0% | 2.3% | ||
| Q3 24 | -26.0% | 9.8% | ||
| Q2 24 | 1.1% | -20.9% | ||
| Q1 24 | -27.2% | -9.4% |
资本支出强度NEOGQDEL
| Q4 25 | 5.2% | — | ||
| Q3 25 | 11.5% | 7.0% | ||
| Q2 25 | 7.1% | 6.1% | ||
| Q1 25 | 14.9% | 8.1% | ||
| Q4 24 | 7.4% | 6.7% | ||
| Q3 24 | 17.7% | 6.4% | ||
| Q2 24 | 10.2% | 5.5% | ||
| Q1 24 | 14.0% | 9.3% |
现金转化率NEOGQDEL
| Q4 25 | — | — | ||
| Q3 25 | 0.30× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
NEOG
| Other | $109.2M | 49% |
| Bacterial And General Sanitation | $44.9M | 20% |
| Services | $25.7M | 11% |
| Natural Toxins And Allergens | $20.4M | 9% |
| Animal Care | $8.9M | 4% |
| Genomics Services | $6.3M | 3% |
| Biosecurity Products | $4.6M | 2% |
| Life Sciences | $1.4M | 1% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
